Transgene

Transgene Cash Flow per Share

The Operating Cash Flow per Share of Transgene (TNG.PA) as of Nov 18, 2026 is -0.20 EUR. In the previous year, Operating Cash Flow per Share was -0.34 EUR — a change of -41.44% (higher).

Cash Flow per Share

-0.20EUR

YoY

-41.44%

Last updated:

Operating Cash Flow per Share of Transgene is 2024 -0.20 EUR. Operating Cash Flow per Share of Transgene was 2023 -0.34 EUR. It decreases by -41.44% higher compared to the previous year.

The Transgene Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2017
-0.56 EUR
Jan 1, 2018
-0.44 EUR
Jan 1, 2019
-0.27 EUR
Jan 1, 2020
-0.34 EUR
Jan 1, 2021
-0.28 EUR
Jan 1, 2022
-0.20 EUR
Jan 1, 2023
-0.34 EUR
Jan 1, 2024
-0.20 EUR
The Transgene Cash Flow per Share history
YEARCash Flow per ShareYoY
-0.20EUR-41.44%
-0.34EUR+68.92%
-0.20EUR-28.25%
-0.28EUR-17.05%
-0.34EUR+25.05%
-0.27EUR-38.30%
-0.44EUR-20.02%
-0.56EUR-4.97%
-0.58EUR-47.72%
-1.12EUR-16.79%
-1.34EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Operating Cash Flow per Share of Transgene is -0.20 EUR in 2024.

Operating Cash Flow per Share of Transgene changed from -0.34 EUR to -0.20 EUR, representing a -41.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Transgene since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene